Astec Lifesciences Ltd
The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries.
Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).[1] [2] [3]
- Market Cap ₹ 2,776 Cr.
- Current Price ₹ 1,417
- High / Low ₹ 1,490 / 825
- Stock P/E
- Book Value ₹ 188
- Dividend Yield 0.11 %
- ROCE -4.50 %
- ROE -11.9 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 7.52 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 1.24% over past five years.
- Company has a low return on equity of 5.96% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
174 | 207 | 267 | 233 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | |
146 | 171 | 213 | 201 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 464 | |
Operating Profit | 28 | 35 | 54 | 32 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -6 |
OPM % | 16% | 17% | 20% | 14% | 21% | 19% | 18% | 16% | 20% | 23% | 12% | -1% |
0 | -0 | -16 | 4 | -8 | 12 | 11 | 12 | 8 | 10 | 13 | 6 | |
Interest | 7 | 9 | 13 | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 |
Depreciation | 12 | 15 | 13 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 |
Profit before tax | 9 | 11 | 13 | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 |
Tax % | 32% | 22% | -17% | 59% | 33% | 37% | 36% | 23% | 27% | 26% | 27% | 24% |
6 | 9 | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | |
EPS in Rs | 3.30 | 4.68 | 7.60 | 2.55 | 9.80 | 17.87 | 18.28 | 24.28 | 33.21 | 45.85 | 13.04 | -23.93 |
Dividend Payout % | 23% | 21% | 16% | 0% | 15% | 8% | 8% | 6% | 5% | 3% | 12% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 1% |
3 Years: | -6% |
TTM: | -27% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -281% |
Stock Price CAGR | |
---|---|
10 Years: | 38% |
5 Years: | 26% |
3 Years: | 1% |
1 Year: | 4% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 11% |
3 Years: | 6% |
Last Year: | -12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 18 | 19 | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
Reserves | 87 | 95 | 116 | 99 | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 350 |
73 | 83 | 93 | 127 | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 494 | |
83 | 88 | 133 | 85 | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 112 | |
Total Liabilities | 261 | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 |
121 | 132 | 133 | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 403 | |
CWIP | 13 | 6 | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 148 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
127 | 146 | 216 | 215 | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 424 | |
Total Assets | 261 | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 15 | 7 | -13 | 19 | 65 | 15 | 168 | -8 | 24 | 75 | 10 | |
-13 | -19 | -19 | -17 | -18 | -49 | -52 | -74 | -73 | -104 | -113 | -135 | |
-2 | 3 | 12 | 31 | -1 | -18 | 37 | -95 | 81 | 80 | 38 | 125 | |
Net Cash Flow | 1 | -1 | -0 | 2 | 1 | -3 | -0 | 0 | 0 | 0 | -0 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 131 | 91 | 142 | 126 | 135 | 122 | 103 | 112 | 123 | 148 | 90 | 135 |
Inventory Days | 145 | 192 | 147 | 177 | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 |
Days Payable | 132 | 114 | 179 | 169 | 116 | 155 | 83 | 218 | 137 | 179 | 161 | 102 |
Cash Conversion Cycle | 145 | 168 | 109 | 134 | 152 | 89 | 142 | 25 | 100 | 145 | 197 | 256 |
Working Capital Days | 122 | 125 | 125 | 142 | 154 | 115 | 147 | 77 | 101 | 163 | 175 | 234 |
ROCE % | 9% | 11% | 20% | 12% | 20% | 22% | 20% | 20% | 22% | 22% | 8% |
Documents
Announcements
- Closure of Trading Window 28 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 Jun - Newspaper Advertisement of 30th AGM of the Company which is going to be conducted through VC / OAVM.
- Update On Family Settlement Agreement Dated April 30, 2024 Under Regulations 30 And 30(7) Of SEBI (LODR) Regulations, 2015. 26 Jun
- Update On Family Settlement Agreement Dated April 30, 2024 Under Regulations 30 And 30(7) Of SEBI (LODR) Regulations, 2015 26 Jun
- Change In Senior Management Personnel Of The Company 24 Jun
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Concalls
-
Nov 2022TranscriptPPT
-
Nov 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Feb 2021TranscriptPPT
Product Portfolio
The company offers a range of products and intermediates, including fungicides, insecticides, herbicides, and various chemical compounds, serving global customers and including triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, fluorinated compounds, halides, intermediates, ketones, ethers, alcohols, and many others. [1]